Benjamin Dryden | Antitrust Attorney | �鶹��ý & Lardner

A man with short blond hair, glasses, and a suit with a red polka dot tie stands in front of a blurred law offices background, reflecting the professionalism of Chicago lawyers.

Benjamin R. Dryden

Partner

Back

Benjamin R. Dryden

Partner

[email protected]

Washington, D.C. 202.945.6128

Sectors

Practice Areas

Education

University of Pennsylvania Law School (J.D., 2008)
- Articles editor, University of Pennsylvania Journal of Constitutional Law
Wharton School
- Certificate in Business and Public Policy 2008
University of Michigan (B.A., 2004)
- Member, Phi Beta Kappa

Admissions

District of Columbia
Maryland
U.S. Court of Appeals
- Fourth, Fifth, Eighth and D.C. Circuits

Benjamin Dryden is an antitrust lawyer and serves as the vice chair of the Firm’s Antitrust & Competition Practice Group. His practice focuses on the antitrust issues that arise in mergers and acquisitions. His experience includes advising on the antitrust risk profiles of potential transactions, counseling clients through the due diligence and integration planning processes, negotiating antitrust risk provisions in purchase agreements, and representing clients in investigations before the Department of Justice, Federal Trade Commission, and state attorneys general. He has particular experience with transactions in the health care, technology, and manufacturing sectors. Benjamin also provides a broad range of antitrust counseling and compliance services, with focuses on the health care industry and in antitrust issues involving labor and employment.

In his M&A practice, Benjamin regularly represents clients in merger investigations before federal and state antitrust enforcers, including “Second Request” merger investigations. Because Second Requests can require sorting through massive volumes of documents in a short amount of time, Benjamin is an expert at leveraging artificial intelligence to achieve the best results in the quickest, most cost-effective way. In 2023, the legal technology company Relativity named Benjamin an “AI Visionary” for his innovative work deploying artificial intelligence in Second Requests.

In addition, Benjamin helps clients navigate the complex requirements of the Hart-Scott-Rodino (HSR) Act. He has prepared well over a hundred HSR filings and routinely advises clients on the intricate HSR reportability rules. He also negotiates and oversees “clean team” agreements to ensure compliant information-sharing throughout the due diligence and integration planning processes.

Benjamin provides a broad range of antitrust counseling services, including answering one-off counseling questions, providing employee trainings, and developing full-scale antitrust compliance programs. Benjamin complements his legal and industry knowledge with a down-to-earth, plain-spoken style, allowing him to effectively communicate complex concepts with a broad range of audiences. Benjamin is a sought-after speaker on antitrust topics, with quotes in publications such as the Wall Street Journal, CNBC.com, Reuters, National Law Journal, and Bloomberg Law, as well as scores of articles and presentations.

Representative Experience

Represented Matterport, Inc., the global leader in 3D digital twin technology, in its $1.7 billion sale to CoStar Group
Represented HonorHealth, a nonprofit health care system serving over five million people in the Phoenix and Scottsdale areas, in its acquisition of multiple health care facilities from Steward Health Care
Represented Quad/Graphics in its $1.4 proposed acquisition of LSC Communications, Inc.
Represented Mary’s Medical Center in merger with Cabell Huntington Hospital
Association of Equipment Manufacturers v. Burgum, 932 F.3d 727 (8th Cir. 2019), 2017 WL 8791104 (D.N.D. 2017) — Successful challenge to the North Dakota Farm Equipment Dealership Statute under the Contracts Clause of the United States Constitution.
Lloyd’s Material Supply Co. v. Regal Beloit Corp., 2017 WL 5172206 (C.D. Cal. 2017) — Achieved full dismissal of antitrust claims on grounds including lack of actionable conduct and lack of plausible antitrust injury.

Awards and Recognition

Mondaq Thought Leadership Award for Antitrust/Competition Law (Fall 2024, Spring 2025)
Recipient, Washington Super Lawyers^® Rising Stars list for Antitrust Litigation (2014-2023)
Artificial Intelligence Visionary, named by Relativity

Presentations and Media

Co-author, “Key Takeaways: 7th Annual “Let’s Talk Compliance,” Health Care Law Today (March 4, 2025)
Speaker, “Antitrust Issues in Provider Mergers & Acquisitions,” 7th Annual Let’s Talk Compliance Conference (January 24, 2025)
Speaker, “Federal and State Updates on Non-Compete Enforceability,” �鶹��ý & Lardner CLE Week (November 11, 2024)
Quoted, “Alaska-Hawaiian Merger, An Aviation Anomaly,” Law360 (September 30, 2024)
Quoted, “,” Manufacturing Dive (May 8, 2024)
Panelist, “Takeaways from the Trenches: The JetBlue/Spirit Merger Trial,” ABA M&A Committee Program (May 3, 2024)
Quoted, “FTC Noncompete Ban Presents Several Trade-Offs For Behavioral Health,” Behavioral Health Business (April 24, 2024)
Quoted, “,” Law360 (April 22, 2024)
�ϳܴǳٱ��,��“,” Law360 (January 17, 2024)
Co-author, “Behind antitrust Enforcers’ 2023 Labor and Employment Push,” Law360 (December 19, 2023)
Quoted, “What the new health counsels at FTC, DOJ, and HHS might do,” STAT (December 19, 2023)
Co-author, “Biden Administration Announces New Efforts to Promote Competition in Health Care,” Health Care Law Today (December 8, 2023)
Quoted, “FTS-Amgen Deal: ‘Major Advance,’ Or ‘Narrow Assurance’?”, Law360 (September 7, 2023)
Co-author, “An Analysis of the “Deputization” Theory of Section 8 of the Clayton Act,” The Antitrust Source (August 2023)
�ϳܴǳٱ��,��“2023 Is Far From Done With Government Merger Cases,” Law360 (July 20, 2023)
Quoted, “DOJ’s Merger Record Improves & Other Early 2023 Highlights,” Law360 (July 7, 2023)
Quoted, “What To Watch In Mass. Courts In The 2nd Half of 2023,” Law360 (July 3, 2023)
Quoted, ““FTC’s Proposed Rule to Ban Noncompetes Faces Stiff Resistance,” WorldatWork (May 31, 2023)
Co-presenter, “Recent Antitrust Developments in Health Care and Pharma” for the ABA Antitrust Law Section’s Health Care and Pharmaceuticals Committee (April 19, 2023)
Quoted, “Analysis: JetBlue faces ‘uphill battle’ in merger fight with government,” Reuters (March 9, 2023)
Speaker, “What the FTC’s Proposed Ban on Employee Noncompetes Means for Healthcare,” Association of Corporate Counsel, Health Law Network (March 7, 2023)
Co-presenter, “Prepare for 2023: What to Expect in Labor & Employment this Year,” �鶹��ý Insights (February 1, 2023)
Quoted, “Nonprofit hospitals may evade noncompete ban enforcement, experts say,” Healthcare Dive (January 20, 2023)
Quoted, “Proposed ban on noncompete clauses could affect ‘every business in the country,’ says attorney — what that means for you,” CNBC (January 11, 2023)
Quoted, “Kroger-Albertsons Antitrust Review Likely to Focus on Local Store Overlap,” The Wall Street Journal (October 21, 2022)
Quoted, “Labor Violations to Receive New Merger Scrutiny Via Agency Pact,” Bloomberg Law (July 22, 2022)
Quoted, “Mid-Year Update: No Antitrust Redux Yet Despite Stack of Bills,” Law360 (July 13, 2022)
Speaker, “Noncompetes under Attack – Biden Administration Seeks to Limit Restrictive Covenants in the United States,” �鶹��ý Insights (July 21, 2021)
Speaker, “A New Doctrine for Trust-Busting: The Evolving View on Antitrust Litigation” (June 2, 2021)
Speaker, “2021 Antitrust Trends in the US” (April 14, 2021)
Co-presenter, “Antitrust Counseling for Health Care Providers,” �鶹��ý Insights (October 22, 2020)
Co-presenter, “Antitrust Update” for the ABA Antitrust Law Section’s Corporate Counseling Committee (February 24, 2020)